Integrated Investment Consultants LLC Has $434,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Integrated Investment Consultants LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 609 shares of the biopharmaceutical company’s stock after buying an additional 39 shares during the period. Integrated Investment Consultants LLC’s holdings in Regeneron Pharmaceuticals were worth $434,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in REGN. Rakuten Securities Inc. grew its stake in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the period. FSA Wealth Management LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $26,000. Fairfield Financial Advisors LTD bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $37,000. Truvestments Capital LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $39,000. Finally, Itau Unibanco Holding S.A. bought a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at about $42,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on REGN. Evercore ISI dropped their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. JPMorgan Chase & Co. dropped their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. BMO Capital Markets dropped their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Canaccord Genuity Group assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. Finally, Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,015.38.

Regeneron Pharmaceuticals Stock Down 1.7 %

Regeneron Pharmaceuticals stock opened at $681.58 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $666.25 and a 1-year high of $1,211.20. The firm has a market capitalization of $74.90 billion, a price-to-earnings ratio of 16.87, a P/E/G ratio of 1.60 and a beta of 0.10. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The firm has a 50 day simple moving average of $738.60 and a 200 day simple moving average of $949.99.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.